- Home
- OGS vs ACAD Comparison
OGS vs ACAD Comparison
Compare OGS & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGS
- ACAD
- Stock Information
- Founded
- OGS 1906
- ACAD 1993
- Country
- OGS United States
- ACAD United States
- Employees
- OGS N/A
- ACAD N/A
- Industry
- OGS Oil/Gas Transmission
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- OGS Utilities
- ACAD Health Care
- Exchange
- OGS Nasdaq
- ACAD Nasdaq
- Market Cap
- OGS 4.3B
- ACAD 4.3B
- IPO Year
- OGS N/A
- ACAD 2004
- Fundamental
- Price
- OGS $75.81
- ACAD $23.61
- Analyst Decision
- OGS Buy
- ACAD Buy
- Analyst Count
- OGS 6
- ACAD 21
- Target Price
- OGS $77.75
- ACAD $29.30
- AVG Volume (30 Days)
- OGS 409.1K
- ACAD 1.9M
- Earning Date
- OGS 11-03-2025
- ACAD 11-05-2025
- Dividend Yield
- OGS 3.53%
- ACAD N/A
- EPS Growth
- OGS 6.57
- ACAD 615.00
- EPS
- OGS 4.21
- ACAD 1.33
- Revenue
- OGS $2,330,032,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- OGS $23.44
- ACAD $14.01
- Revenue Next Year
- OGS $4.32
- ACAD $11.72
- P/E Ratio
- OGS $18.01
- ACAD $17.82
- Revenue Growth
- OGS 13.43
- ACAD 14.41
- 52 Week Low
- OGS $66.38
- ACAD $13.40
- 52 Week High
- OGS $82.25
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- OGS 53.80
- ACAD 39.78
- Support Level
- OGS $74.06
- ACAD $23.70
- Resistance Level
- OGS $76.00
- ACAD $25.90
- Average True Range (ATR)
- OGS 0.97
- ACAD 0.74
- MACD
- OGS -0.10
- ACAD -0.33
- Stochastic Oscillator
- OGS 63.00
- ACAD 8.16
About OGS ONE Gas Inc.
ONE Gas Inc is a regulated natural gas utility company. It is involved in the distribution and sale of natural gas to residential, commercial, industrial, and transportation consumers through its network of pipelines and service lines. Almost all of the company's revenue is derived from natural gas sales in the states of Oklahoma, Kansas, and Texas. The company controls considerable market shares in Oklahoma and Kansas.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.